ArticleCureus2025
The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic intracranial hypertension (IIH) and polycystic ovary syndrome (PCOS) are strongly associated with obesity in women of reproductive age. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been extensively reported to facilitate weight loss through central satiety. Emerging evidence demonstrates additional benefits of GLP-1 RAs. Exenatide exerts direct effects on choroid plexus receptors, reducing cerebrospinal fluid (CSF) secretion and intracranial pressure (ICP), and on the ovary, enhancing follicular maturation, restoring ovulation, and improving fertility outcomes in PCOS. A 29-year-old woman with PCOS was referred from gynecology for assessment of intermittent visual blurring and chronic headaches. Ophthalmic examination revealed normal monocular visual acuity of 6/5 in each eye but reduced binocular vision of 6/12, associated with double vision. She also reported a weight gain of 15 kg over eight months. Fundoscopy was unremarkable, with no optic disc swelling. IIH without papilledema (IIHWOP) was diagnosed based on magnetic resonance imaging showing an enlarged pituitary fossa, partial empty sella, and optic nerve sheath dilatation, with lumbar puncture confirming a raised opening pressure of 280 mmH₂O and normal CSF. Initial treatment with acetazolamide was discontinued due to intolerance. Exenatide was subsequently initiated, leading to early improvement in headache frequency and diplopia, independent of weight loss. Menstrual cycles, hormonal profile, and insulin resistance also improved beyond the effect of metformin alone. This case highlights the potential of exenatide to provide dual therapeutic benefits in IIH and PCOS, acting through direct receptor-mediated pathways to reduce ICP, improve headaches, and restore ovulatory cycles, and indirectly through the reduction of central obesity. Further studies are warranted to establish its role in the combined management of these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.